Conclusion
We are hypothesizing that the profuse presence of ACE 2 and its
upregulation in different pathological conditions making patients more
susceptible to SARS-CoV-2 infection and can contribute to an increase in
co-morbidity and mortality. COVID-19 is a global concern and its
pathophysiology is very complex which creating an illusion towards the
use of first-line drugs in the treatments of preeclampsia,
cardiovascular diseases, diabetes and its complications, asthma, NASH,
immune-related diseases and cancer. Hence, there is an urgent need for
care to those patients who have SARS-CoV-2 infection underlying with
multiple diseases and its delay in diagnosis may increase the severity
and mortality in comorbid conditions due to multi-organ transmission of
infection with a heavy load of virus and cytokine storm (Figure 1).
Hence targeting the interaction of SARS-CoV-2 to ACE 2 could be the
future novel therapeutic approach to alleviate the multi-organ
transmission and failure.